originally by: The Guardian
published: 15 May 2013
A drug manufacturer based in Britain has vowed to add new restrictions to sales of its products in the US after it was revealed that it sold a batch of barbiturate to the Arkansas department of corrections, which intended to use it in executions.
Hikma Pharmaceuticals has promised to put in place “concrete steps to restrict the supply of its products for unintended uses” following the disclosure by the legal action charity Reprieve that a wholly owned subsidiary in the US had sold injectable phenobarbital to the Arkansas prison service which was seeking to devise a new way of killing its death-row inmates.
“Hikma strongly objects to the use of any of its products in capital punishment,” the company said in a statement.
Hikma is the latest pharmaceutical company to be caught selling death penalty drugs to the US amid a growing boycott across Europe and around the world of lethal injection drug sales to capital punishment states.